Squarepoint
LSTA icon

Squarepoint’s Lisata Therapeutics LSTA Stock Holding History

Squarepoint’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,376
Closed -$30K – 3399
2020
Q4 		$30K Buy
+1,376
New +$32.7K ﹤0.01% 2828
2015
Q3 		– Sell
-364
Closed -$102K – 510
2015
Q2 		$102K Buy
+364
New +$135K 0.03% 407

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Squarepoint's LSTA Position: Q1 2021 in Review

Squarepoint sold out of Lisata Therapeutics (LSTA) in Q1 2021, closing a stake of 1,376 shares — an estimated $30K sold.

Squarepoint first reported a position in LSTA in Q2 2015 and held it in 2 quarters. The position peaked at $102K in Q2 2015. 32 funds tracked by Wall St. Rank hold LSTA as of Q1 2021.

  • Squarepoint reported no remaining Lisata Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Squarepoint sold 1,376 Lisata Therapeutics shares in Q1 2021, an estimated $30K.
  • Squarepoint first reported a position in Lisata Therapeutics in Q2 2015 and held it in 2 quarters.
  • Squarepoint's Lisata Therapeutics position peaked at $102K in Q2 2015.
  • 32 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2021.

Based on Squarepoint's 13F filing for Q1 2021, filed 17 May 2021.